STRO.NASDAQSutro Biopharma, INC
Form 4: Sutro Biopharma Director James P. Panek Acquires 35,000 Stock Options
Sentiment:
SEC Form 4 Filing
Director James P. Panek acquired 35,000 stock options in Sutro Biopharma, Inc. on June 6, 2024.
Summary
- On June 6, 2024, James P. Panek, a director of Sutro Biopharma, Inc., acquired 35,000 stock options.
- The options have an exercise price of $3.76.
- The options vest monthly starting July 6, 2024, with full vesting by the earlier of the 2025 annual stockholders meeting or June 6, 2025.
- The options expire on June 6, 2034.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director.
Industry Context
This is a standard disclosure related to insider transactions, common in the biopharmaceutical industry.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment, reflecting confidence from a company director.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of transaction: James P. Panek acquired 35,000 stock options. |
| 07/06/2024 | Options begin to vest monthly. |
| 06/06/2025 | Options fully vested, or earlier if the 2025 annual stockholders meeting occurs before this date. |
| 06/06/2034 | Expiration date of the stock options. |
| 06/10/2024 | Date of filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.